The World Health Organization may declare an international public health emergency over Ebola and will convene a panel of experts in coming days to explore the use of experimental treatments, The New York Times NYT +0.70%writes. A treatment developed by Mapp Biopharmaceutical was given two infected American health workers whose conditions have improved. Before the WHO announcement, the Nigerian health ministry had written to the U.S. Centers for Disease Control and Prevention requesting access to the drug.
Sarepta Therapeutics of Cambridge wants the federal government to approve immediate use of the company's experimental drug for the treatment of Ebola, the Boston Globe reports.
The Globe says the treatment has worked in a majority of Ebola-infected monkeys on which it was used and has been found safe for humans, but has not been used to treat Ebola-infected humans.
You must dose the older DMD boys every day or at least every two days with this drug.When dosing at a early age you will delay progression by 1/3 with every seven day dosing, however if you steady the dosing where it is in a constant use of your drug you will greatly expand the benefits and delay the progression by more than 1/2 or by even 2/3...........Once your drug leaves to body of the treated boy you will have every week a 4-5 day progression effect coming back,this is why you see a difference in 3 years.
Sarepta Declines Comment on Rumored Partnership with Bristol-Myers Squibb
Charles Gross, Benzinga Staff Writer
July 15, 2014 1:03 PM
SURE SEEMS LIKE WE WILL,MAYBE EVEN A PARTNERSHIP?
Our RNA technology platform is based on our pioneering work with phosphorodiamidate morpholino oligomer—or PMO—chemistries, a versatile platform that may power the rapid design and development of new treatments for difficult-to-address serious and life-threatening diseases
I bet he will come out with ebola words as well to let everyone know ''we have a drug for ebola'' why not take the free press
HDTRA1-13-C-0018-P00003 Notice Type:
Added: Jul 22, 2014 1:36 pm
Notice of Intent to Award a Sole Source Contract
The Defense Threat Reduction Agency (DTRA) intends to negotiate and award a sole source modification to current contract HDTRA1-13-C-0018 to MAPP Biopharmaceutical. This is follow-on research to a current contract which focuses on development of a monoclonal antibody cocktail for Ebola Zaire. The proposed work comprises specific, additional tasks which are justified by the promising results from the work already conducted under the current contract. The two additional tasks are 1) to prepare and submit an Investigational New Drug (IND) application package to the Food and Drug Administration (FDA) for ZMappTM, and 2) to provide cGMP grade ZMappTM in sufficient quantity to perform a Phase 1 clinical safety study. The additional tasks will be performed within the current period of performance of 12 months. The work being added will be done so on a cost plus fixed fee basis. The North American Industry Classification System (NAICS) is 541711 and the Product Service Code (PSC) is AD92. THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. Interested parties have fifteen (15) days from the date of this notice, to submit in writing, to the identified point of contact, clear and convincing evidence of their qualifications and/or capabilities.
hard to believe but EU likes growth and will do anything to get alike drugs approved before U S drugs ..Sarepta's blows all dmd drugs out the water.